BioStock: Spago Nanomedical looks ahead

First North-listed Spago Nanomedical has started the year with positive news from both the SpagoPix and the Tumorad projects. The company's financial status was recently reported when publishing the interim results for the fourth quarter of 2021. BioStock contacted CEO Mats Hansen for a comment and a forward view.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/02/spago-nanomedical-looks-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/